PainQx is a software diagnostic company that has developed a next-generation approach to pain measurement objectively. The PainQx platform succeeds in this by evaluating the patient's neuronal activity, processing and decoding the data collected through a proprietary algorithm. The output is a biomarker of pain and neuronal responses reported on a scale, on the degree corresponding to the patient's state of pain
Sooma Oy is developing, manufacturing and marketing a non-invasive therapy device for neurological and psychiatric disorders (depression and chronic pain). Sooma uses transcranial direct current stimulation (tDCS) technology. Sooma technology is trusted by over 100 clinics worldwide. Their first product is the first portable device approved for treatment of major depressive disorder (MDD). The device is CE-approved and currently marketed in the EU and other selected markets. Their quality management system has been awarded with ISO 13485:2016 and MDSAP certificates.
SOOMA closes an investment round of over 1.2 Million EUR
Thanks to the capital increase from IAG members and Athensmed, the startup aims to take its drug-free therapy for depression to worldwide market.Leggi